Lars Gunnar Larsson

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. doi request reprint The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy
    Lars Gunnar Larsson
    Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, Box 280, 171 77 Stockholm, Sweden
    Exp Cell Res 316:1429-37. 2010
  2. doi request reprint Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
    Lars Gunnar Larsson
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, SE 171 77 Stockholm, Sweden
    Semin Cancer Biol 21:367-76. 2011
  3. pmc Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation
    Fuad Bahram
    Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, Stockholm, Sweden
    Oncotarget 7:2837-54. 2016
  4. doi request reprint Tipping the balance: Cdk2 enables Myc to suppress senescence
    Per Hydbring
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
    Cancer Res 70:6687-91. 2010
  5. pmc Cdk2: a key regulator of the senescence control function of Myc
    Per Hydbring
    Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, 171 77 Stockholm, Sweden
    Aging (Albany NY) 2:244-50. 2010
  6. doi request reprint MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence
    Vedrana Tabor
    Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, Stockholm, Sweden Department of Medical Biochemistry and Biophysics MBB, Karolinska Institute, Stockholm, Sweden
    Cancer Res 74:4222-9. 2014
  7. pmc CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer
    Diana Cepeda
    Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
    EMBO Mol Med 5:1067-86. 2013
  8. pmc Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage
    Lina Guerra
    Department of Cell Biology, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 5:e8924. 2010
  9. doi request reprint Methods to study MYC-regulated cellular senescence
    Vedrana Tabor
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden
    Methods Mol Biol 1012:99-116. 2013
  10. pmc Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia
    Kari Högstrand
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    PLoS ONE 7:e31366. 2012

Collaborators

  • Mikael Lerner
  • Nadine Hein
  • Martin Widschwendter
  • Olle Sangfelt
  • Christine Josenhans
  • Bo Stenerlow
  • Erik Fredlund
  • Lina Guerra
  • Birgitta Sander
  • Per Hydbring
  • Vedrana Tabor
  • Fuad Bahram
  • Kari Högstrand
  • Siti Mariam Zakaria
  • Helen Nilsson
  • Matteo Bocci
  • Natalie von der Lehr
  • Diana Cepeda
  • Susanna Tronnersjö
  • Bernhard Luscher
  • Yingtao Su
  • Hamid Reza Sharifi
  • Alf Grandien
  • Alina Castell
  • Sara Fahlén
  • Oliver Frings
  • Jacob Goodwin
  • Raoul Kuiper
  • Nyosha Alikhani
  • Francesc Vinals
  • James Wohlschlegel
  • Cristina Al Khalili Szigyarto
  • Kristina Magnusson
  • Hwee Fang Ng
  • Sanjay Navani
  • Nimesh Bhaskaran
  • Alena Malyukova
  • Vanessa Soto Cerrato
  • Stefan Grotegut
  • Dan Grander
  • Salah Mahmoudi
  • Fredrik Ponten
  • Michael Lund Nielsen
  • Charles Spruck
  • Daniel Klevebring
  • Juha Rantala
  • Karin Jirstrom
  • Aldwin Suryo Rahmanto
  • Dahui Sun
  • Mathias Uhlen
  • Eduar Hejll
  • Bjorn Rozell
  • Jörg Vervoorts
  • Siqin Wu
  • Richard Lilischkis
  • Marie Henriksson

Detail Information

Publications11

  1. doi request reprint The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy
    Lars Gunnar Larsson
    Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, Box 280, 171 77 Stockholm, Sweden
    Exp Cell Res 316:1429-37. 2010
    ....
  2. doi request reprint Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
    Lars Gunnar Larsson
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, SE 171 77 Stockholm, Sweden
    Semin Cancer Biol 21:367-76. 2011
    ..This can hopefully form the basis for a "pro-senescence therapy" strategy to combat cancer in the future...
  3. pmc Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation
    Fuad Bahram
    Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, Stockholm, Sweden
    Oncotarget 7:2837-54. 2016
    ..Further, these conditions correlated with favorable tumor stage and patient outcome. This novel regulation of Myc by IFN-γ/p27(KIP1) potentially offers new possibilities for therapeutic intervention in tumors with deregulated Myc...
  4. doi request reprint Tipping the balance: Cdk2 enables Myc to suppress senescence
    Per Hydbring
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
    Cancer Res 70:6687-91. 2010
    ....
  5. pmc Cdk2: a key regulator of the senescence control function of Myc
    Per Hydbring
    Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, 171 77 Stockholm, Sweden
    Aging (Albany NY) 2:244-50. 2010
    ..Importantly, selective pharmacological inhibition of Cdk2 forced Myc/Ras expressing cells into cellular senescence, highlighting this kinase as a potential therapeutic target for treatment of tumors driven by Myc or Ras...
  6. doi request reprint MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence
    Vedrana Tabor
    Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, Stockholm, Sweden Department of Medical Biochemistry and Biophysics MBB, Karolinska Institute, Stockholm, Sweden
    Cancer Res 74:4222-9. 2014
    ..These findings contribute to our understanding of the neoplastic transformation process, with implications for future treatment strategies...
  7. pmc CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer
    Diana Cepeda
    Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
    EMBO Mol Med 5:1067-86. 2013
    ....
  8. pmc Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage
    Lina Guerra
    Department of Cell Biology, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 5:e8924. 2010
    ..In response to genotoxic agents, cells overexpressing MYC undergo apoptosis. However, the MYC-regulated effectors acting upstream of the mitochondrial apoptotic pathway are still unknown...
  9. doi request reprint Methods to study MYC-regulated cellular senescence
    Vedrana Tabor
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden
    Methods Mol Biol 1012:99-116. 2013
    ..This may form the basis for new concepts of pro-senescence therapy to combat MYC in cancer. ..
  10. pmc Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia
    Kari Högstrand
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    PLoS ONE 7:e31366. 2012
    ..In conclusion, our findings provide direct evidence that BCL-X(L) and BCL-2 but not FLIP(L) acts in synergy with MYC to drive AML development...
  11. pmc Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
    Per Hydbring
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Proc Natl Acad Sci U S A 107:58-63. 2010
    ..Finally, our findings highlight that pharmacological inhibition of Cdk2 activity is a potential therapeutical principle for cancer therapy, in particular for tumors with activated Myc or Ras...